10.1002/anie.201706809
Angewandte Chemie International Edition
COMMUNICATION
[4] a) K. B. Seamon, J. W. Daly, H. Metzger, N. J. de Souza, J. Reden, J. Med.
Chem. 1983, 26, 436439; b) J. D. Robbins, D. L. Boring, W.-J. Tang, R.
Shank, K. B. Seamon, J. Med. Chem. 1996, 39, 27452752; c) T. Onda, Y.
Hashimoto, M. Nagai, H. Kuramochi, S. Saito, H. Yamazaki, Y. Toya, I. Sakai,
C. J. Homcy, K. Nishikawa, Y. Ishikawa, J. Biol. Chem. 2001, 276,
4778547793; d) C. Pinto, D. Papa, M. Hübner, T.-C. Mou, G. H. Lushington,
R. Seifert, J. Pharmacol. Exp. Ther. 2008, 325, 2736.
[23] We were unable to advance this early isoxazole intermediate (15) due to
the robust nature of the oxacycle.
N. Ogawa, Jpn. J. Clin. Pharmacol. Ther. 1997, 28, 583602.
[6] a) F. E. Ziegler, B. H. Jaynes, M. T. Saindane, Tetrahedron Lett. 1985, 26,
3307–3310; b) F. E. Ziegler, B. H. Jaynes, M. T. Saindane, J. Am. Chem.
Soc. 1987, 109, 8115–8116; c) F. E. Ziegler, B. H. Jaynes, Tetrahedron Lett.
1987, 28, 2339–2342; d) F. E. Ziegler, B. H. Jaynes, Tetrahedron Lett. 1988,
29, 2031–2032; e) E. J. Corey, P. Da Silva Jardine, J. C. Rohloff, J. Am.
Chem. Soc. 1988, 110, 3672–3673; f) E. J. Corey, P. Da Silva Jardine, T.
Mohri, Tetrahedron Lett. 1988, 29, 6409–6412; g) E. J. Corey, P. Da Silva
Jardine, Tetrahedron Lett. 1989, 30, 7297–7300; h) S. Hashimoto, S. Sakata,
M. Sonegawa, S. Ikegami, J. Am. Chem. Soc. 1988, 110, 3670–3672.
[7] a) B. Delpech, D. Calvo, R. Lett, Tetrahedron Lett. 1996, 37, 1015–1018; b)
B. Delpech, D. Calvo, R. Lett, Tetrahedron Lett. 1996, 37, 1019–1022.
[8] a) For a review of the field until 1992, see: M. I. Colombo, J. Zinczuk, E. A.
Ruveda, Tetrahedron 1992, 48, 963–1037; b) J. J. Harnett, J. K. Sutherland,
H. Yang, J. Chem. Soc.-Perkin Trans. 1 1995, 1391–1395; c) M. Leclaire, R.
Levet, F. Péricaud, L. Ricard, J. Y. Lallemand, Tetrahedron 1996, 52, 7703–
7718; d) M. Leclaire, R. Levet, F. Ferreira, P. H. Ducrot, J. Y. Lallemand, L.
Ricard, Chem. Commun. 2000, 1737–1738; e) A. Anikin, M. Maslov, J. Sieler,
S. Blaurock, J. Baldamus, L. Hennig, M. Findeisen, G. Reinhardt, R. Oehme,
P. Welzel, Tetrahedron 2003, 59, 5295–5305 and references therein; f) H.
Ye, G. Deng, J. Liu, F. G. Qiu, Org. Lett. 2009, 11, 5442–5444.
[9] (a) F. Kienzle, J. Stadlwieser, I. Mergelsberg, Helv. Chim. Acta 1989, 72,
348–352; b) F. Kienzle, J. Stadlwieser, W. Rank, P. Schönholzer, Helv. Chim.
Acta 1990, 73, 1108–1139.
[10] G. Bold, S. Chao, R. Bhide, S.-H. Wu, D. V. Patel, C. J. Sih, C. Chidester,
Tetrahedron Lett. 1987, 28, 1973–1976.
[11] D. Liotta, M. Saindane, U. Sunay, W. C. L. Jamison, J. Grossman, P.
Phillips, J. Org. Chem. 1985, 50, 3241–3243.
[12] In agreement with the previous reports (see ref. 9b), attempted additions of
sp3 or sp2 organometallic nucleophiles to cis-decalin 3 were problematic.
[13] a) W. G. Dauben, D. M. Michno, J. Org. Chem. 1977, 42, 682–685; b) P.
Sundararaman, W. Herz, J. Org. Chem. 1977, 42, 813819; c) W. S. Cheung,
H. N. C. Wong, Tetrahedron Lett. 1998, 39, 6521–6524.
[14] a) A. Padwa, W. H. Pearson, Eds., Synthetic Applications of 1,3-Dipolar
Cycloaddition Chemistry Toward Heterocycles and Natural Products, John
Wiley & Sons, Inc., New York, USA, 2002; b) H. Feuer, K. Torssell, Eds.,
Nitrile Oxides, Nitrones, and Nitronates in Organic Synthesis: Novel
Strategies in Synthesis, Wiley-Interscience, Hoboken, N.J., 2008.
[15] P. Beltrame, P. Sartirana, C. Vintani, J. Chem. Soc. B-Phys. Org. 1971,
814817 and references therein.
[16] a) C. Praveen, A. Kalyanasundaram, P. T. Perumal, Synlett 2010, 777–781;
b) S. Murarka, A. Studer, Org. Lett. 2011, 13, 2746–2749.
[17] A more direct construction of the decalinisoxazole CC bond linkage using
metal-catalyzed cross-couplings proved difficult (unpublished results).
[18] a) S. Hashimoto, M. Sonegawa, S. Sakata, S. Ikegami, J. Chem. Soc.-
Chem. Commun. 1987, 24–25; b) K. C. Nicolaou, S. Kubota, W. S. Li, J.
Chem. Soc.-Chem. Commun. 1989, 512–514.
[19] P. Dupau, R. Epple, A. A. Thomas, V. V. Fokin, K. B. Sharpless, Adv. Synth.
Catal. 2002, 344, 421–433.
[20] tert-Butyldimethylsilyl ether 9 (see Scheme 1) was unreactive under these
conditions.
[21] For an unusual reactivity observed during our early studies, see: R. Kučera,
O. Hylse, M. Babiak, J. Švenda, Tetrahedron Lett. 2015, 56, 61716173.
[22] For an example of low-yielding isoxazoline formation using an oxime
precursor structurally related to 17, see: A. Barco, S. Benetti, G. Spalluto, A.
Casolari, G. P. Pollini, V. Zanirato, P. G. Baraldi, Il Farmaco 1991, 46, 1281–
1295.
This article is protected by copyright. All rights reserved.